Literature DB >> 23468820

Fecal transplant in refractory Clostridium difficile colitis.

Alexander Kleger1, Jacqueline Schnell, Andreas Essig, Martin Wagner, Martin Bommer, Thomas Seufferlein, Georg Härter.   

Abstract

BACKGROUND: Clostridium difficile infections are becoming more common, more severe, and more likely to recur. Conventional treatment with antibiotics often fails to eradicate the infection; even when it succeeds, recurrent infection is common. Complementary treatment with probiotic agents to reconstitute the physiological intestinal flora does not yield any consistent benefit. In recent years, fecal transplantation has been used in the English-speaking countries with cure rates of about 87%, but the available evidence is limited to large case series. No randomized controlled trials have been performed. We present the case of a 73-year-old woman with intractable, recurrent enterocolitis due to Clostridium difficile who was successfully treated with fecal transplantation via colonoscopy. CASE DESCRIPTION: Upon the completion of antibiotic treatment for a second recurrence of enterocolitis, stool in liquid suspension was introduced into the patient's colon through a colonoscope. Prior testing had shown the stool donor to be free of acute infection or stool pathogens. The patient was given loperamide to prolong contact of the stool transplant with the colonic mucosa. She was also treated with Saccharomyces cerevisiae for four weeks. COURSE: There was no clinical or microbiological evidence of a further recurrence of enterocolitis for 6 months after transplantation. Stool transplantation had no adverse effects.
CONCLUSION: This patient had a lasting remission of enterocolitis due to Clostridium difficile after the treatment described above. Fecal transplantation seems to be a safe and highly effective treatment for recurrent Clostridium difficile infection. It is unclear whether the administration of Saccharomyces cerevisiae confers any additional benefit.

Entities:  

Mesh:

Year:  2013        PMID: 23468820      PMCID: PMC3585452          DOI: 10.3238/arztebl.2013.0108

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN: 1866-0452            Impact factor:   5.594


  65 in total

Review 1.  Probiotics in perspective.

Authors:  Fergus Shanahan
Journal:  Gastroenterology       Date:  2010-10-19       Impact factor: 22.682

2.  Fidaxomicin versus vancomycin for Clostridium difficile infection.

Authors:  Thomas J Louie; Mark A Miller; Kathleen M Mullane; Karl Weiss; Arnold Lentnek; Yoav Golan; Sherwood Gorbach; Pamela Sears; Youe-Kong Shue
Journal:  N Engl J Med       Date:  2011-02-03       Impact factor: 91.245

Review 3.  Treatment of refractory and recurrent Clostridium difficile infection.

Authors:  Christina M Surawicz; Jacob Alexander
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-04-19       Impact factor: 46.802

4.  Endoscopic fecal microbiota transplantation: "first-line" treatment for severe clostridium difficile infection?

Authors:  Lawrence J Brandt; Thomas Julius Borody; Jordana Campbell
Journal:  J Clin Gastroenterol       Date:  2011-09       Impact factor: 3.062

Review 5.  Tigecycline for the treatment of severe Clostridium difficile infection.

Authors:  Kelly C Larson; Paul P Belliveau; Linda M Spooner
Journal:  Ann Pharmacother       Date:  2011-07-05       Impact factor: 3.154

Review 6.  Rifaximin: new therapeutic indication and future directions.

Authors:  Anastasia Rivkin; Suzanna Gim
Journal:  Clin Ther       Date:  2011-07-07       Impact factor: 3.393

Review 7.  Review article: faecal transplantation therapy for gastrointestinal disease.

Authors:  J Landy; H O Al-Hassi; S D McLaughlin; A W Walker; P J Ciclitira; R J Nicholls; S K Clark; A L Hart
Journal:  Aliment Pharmacol Ther       Date:  2011-06-20       Impact factor: 8.171

8.  Clostridium difficile infection in Europe: a hospital-based survey.

Authors:  Martijn P Bauer; Daan W Notermans; Birgit H B van Benthem; Jon S Brazier; Mark H Wilcox; Maja Rupnik; Dominique L Monnet; Jaap T van Dissel; Ed J Kuijper
Journal:  Lancet       Date:  2011-01-01       Impact factor: 79.321

9.  Recommendations for probiotic use-2011 update.

Authors:  Martin H Floch; W Allan Walker; Karen Madsen; Mary Ellen Sanders; George T Macfarlane; Harry J Flint; Levinus A Dieleman; Yehuda Ringel; Stefano Guandalini; Ciaran P Kelly; Lawrence J Brandt
Journal:  J Clin Gastroenterol       Date:  2011-11       Impact factor: 3.062

10.  Results of faecal donor instillation therapy for recurrent Clostridium difficile-associated diarrhoea.

Authors:  Kjetil Garborg; Bjørn Waagsbø; Asbjørn Stallemo; Jon Matre; Anders Sundøy
Journal:  Scand J Infect Dis       Date:  2010-07-22
View more
  7 in total

1.  [Recurrent Clostridium difficile infection. Treatment with duodenal infusion of donor feces].

Authors:  T Seufferlein; A Kleger; S Nitschmann
Journal:  Internist (Berl)       Date:  2014-04       Impact factor: 0.743

Review 2.  Clostridium difficile infection: guideline-based diagnosis and treatment.

Authors:  Christoph Lübbert; Endres John; Lutz von Müller
Journal:  Dtsch Arztebl Int       Date:  2014-10-24       Impact factor: 5.594

3.  Complicated fecal microbiota transplantation in a tetraplegic patient with severe Clostridium difficile infection.

Authors:  Thorsten Brechmann; Justyna Swol; Veronika Knop-Hammad; Jörg Willert; Mirko Aach; Oliver Cruciger; Wolff Schmiegel; Thomas A Schildhauer; Uwe Hamsen
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

4.  Fecal Microbiota Transplant in Patients With Recurrent Clostridium Difficile Infection.

Authors:  Stefan Hagel; Anne Fischer; Philipp Ehlermann; Thorsten Frank; Kester Tueffers; Andreas Sturm; Alexander Link; Muenevver Demir; Arno Siebenhaar; Martin Storr; Thomas Glueck; Erhard Siegel; Philip Solbach; Felix Goeser; Christian B. Koelbel; Ansgar Lohse; Christoph Luebbert; Ulrich Kandzi; Matthias Maier; Stefanie Schuerle; Markus M. Lerch; Daniela Tacke; Oliver A. Cornely; Andreas Stallmach; Maria Vehreschild
Journal:  Dtsch Arztebl Int       Date:  2016-09-05       Impact factor: 5.594

5.  Probiotics for the treatment of Clostridium difficile associated disease.

Authors:  Leo R Fitzpatrick
Journal:  World J Gastrointest Pathophysiol       Date:  2013-08-15

6.  Minimum Requirements for Reporting Fecal Microbiota Transplant Trial.

Authors:  Shirin Moossavi; Faraz Bishehsari; Reza Ansari; Homayoon Vahedi; Siavosh Nasseri-Moghaddam; Shahin Merat; Iradj Sobhani; Ali Keshavarzian; Reza Malekzadeh
Journal:  Middle East J Dig Dis       Date:  2015-07

Review 7.  Relationship between intestinal microbiota and ulcerative colitis: Mechanisms and clinical application of probiotics and fecal microbiota transplantation.

Authors:  Zhao-Hua Shen; Chang-Xin Zhu; Yong-Sheng Quan; Zhen-Yu Yang; Shuai Wu; Wei-Wei Luo; Bei Tan; Xiao-Yan Wang
Journal:  World J Gastroenterol       Date:  2018-01-07       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.